Cargando…

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

While pralatrexate (PDX) has been successfully developed for the treatment of T‐cell lymphoma, the mechanistic basis for its T‐cell selectivity and acquired resistance remains elusive. In an effort to potentially identify synergistic combinations that might circumnavigate or delay acquired PDX resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scotto, Luigi, Kinahan, Cristina, Casadei, Beatrice, Mangone, Michael, Douglass, Eugene, Murty, Vundavalli V., Marchi, Enrica, Ma, Helen, George, Changchun, Montanari, Francesca, Califano, Andrea, O'Connor, Owen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540375/ https://www.ncbi.nlm.nih.gov/pubmed/32614991 http://dx.doi.org/10.1002/gcc.22884

Ejemplares similares

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
por: Kinahan, Cristina, et al.
Publicado: (2020)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways
por: Scotto, Luigi, et al.
Publicado: (2021)

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest
por: Scotto, Luigi, et al.
Publicado: (2020)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB
por: Kalac, Matko, et al.
Publicado: (2020)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway
por: Weng, Wanwen, et al.
Publicado: (2022)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series
por: Ma, Helen, et al.
Publicado: (2020)

Outer Membrane Disruption Overcomes Intrinsic, Acquired, and Spontaneous Antibiotic Resistance
por: MacNair, Craig R., et al.
Publicado: (2020)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance
por: Stokes, Jonathan M., et al.
Publicado: (2017)

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
por: Song, Xiangping, et al.
Publicado: (2020)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
por: Innao, Vanessa, et al.
Publicado: (2021)

A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance
por: Qu, Fanjie, et al.
Publicado: (2021)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
por: Izbicka, E., et al.
Publicado: (2009)

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
por: Tedeschi, Philip M., et al.
Publicado: (2014)

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
por: Tedeschi, Philip M., et al.
Publicado: (2015)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Overcoming Intrinsic and Acquired Resistance Mechanisms Associated with the Cell Wall of Gram-Negative Bacteria
por: Impey, Rachael E., et al.
Publicado: (2020)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy
por: Li, Ling, et al.
Publicado: (2020)

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
por: Singh, Sunanda, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_849rf6bqnda46362qmnvfnbcgc